Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis

Kathleen E. Corey*, Mary E. Rinella

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations


Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in the USA with a growing prevalence worldwide. Nonalcoholic steatohepatitis (NASH), progressive form of NAFLD, can lead to the development of cirrhosis, hepatocellular carcinoma, and the need for liver transplantation. Treatment of NASH may decrease the risk of progressive disease. Treatment for NAFLD should center around weight loss and exercise. Pharmacotherapy with vitamin E and pioglitazone should be considered for those with NASH, especially those with fibrosis. Weight loss surgery is also an effective treatment for NASH in individuals with other indications for surgery. In this review, we will discuss the currently available therapies for NASH including lifestyle, pharmacologic, and surgical options.

Original languageEnglish (US)
Pages (from-to)1387-1397
Number of pages11
JournalDigestive diseases and sciences
Issue number5
StatePublished - May 1 2016


  • Nonalcoholic fatty liver disease
  • Nonalcoholic steatohepatitis
  • Pioglitazone
  • Vitamin E
  • Weight loss surgery

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology


Dive into the research topics of 'Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis'. Together they form a unique fingerprint.

Cite this